LVTX Stock Overview
A clinical-stage immuno-oncology company, focuses on developing cancer treatments.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LAVA Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.80 |
| 52 Week High | US$6.47 |
| 52 Week Low | US$1.13 |
| Beta | 0.53 |
| 11 Month Change | -10.89% |
| 3 Month Change | -31.82% |
| 1 Year Change | 4.65% |
| 33 Year Change | -74.29% |
| 5 Year Change | n/a |
| Change since IPO | -87.41% |
Recent News & Updates
Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive
Jun 02
Recent updates
Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive
Jun 02LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry?
Mar 01LAVA Therapeutics: Assessing A Promising Innovator
Oct 18LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.30, revenue of $0.47M beats by $0.11M
Sep 13Shareholder Returns
| LVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.7% | 4.7% | 3.1% |
| 1Y | 4.7% | 15.1% | 24.9% |
Return vs Industry: LVTX underperformed the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: LVTX underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| LVTX volatility | |
|---|---|
| LVTX Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LVTX's share price has been volatile over the past 3 months.
Volatility Over Time: LVTX's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Steve Hurly | www.lavatherapeutics.com |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
LAVA Therapeutics N.V. Fundamentals Summary
| LVTX fundamental statistics | |
|---|---|
| Market cap | US$47.59m |
| Earnings (TTM) | -US$24.18m |
| Revenue (TTM) | US$7.40m |
6.4x
P/S Ratio-2.0x
P/E RatioIs LVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LVTX income statement (TTM) | |
|---|---|
| Revenue | US$7.40m |
| Cost of Revenue | US$164.00k |
| Gross Profit | US$7.23m |
| Other Expenses | US$31.42m |
| Earnings | -US$24.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 97.78% |
| Net Profit Margin | -326.89% |
| Debt/Equity Ratio | 12.6% |
How did LVTX perform over the long term?
See historical performance and comparison